Logo

Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris

Share this

Yuhan Signs an Exclusive License Agreement with Glenmark for its Ryaltris

Shots:
  • Glenmark to receive upfront- milestones and royalties on sales from Yuhan. Yuhan to get exclusive commercialization rights for Glenmark’s Ryaltris in South Korea
  • Yuhan will be responsible for its regulatory approval and Glenmark to take care of manufacturing and supply of Ryaltris in South Korea
  • Ryaltrisis a FD combination of anti-histamine and steroid i.e olopatadine hydrochloride (665 mcg) & mometasone furoate (25 mcg) indicated to treat symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age. In May 2018 Glenmark filled Ryaltris’ NDA to the US FDA and is currently reviewed
Ref: Glenmark | Image: DNA India

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions